Evidence map›Paper›PMID 37901231›Full record

ArticleFrontiers in immunology2023

Tolerogenic dendritic cells generated

Gillian Dao Nyesiga, Lieneke Pool, Pavlos C Englezou, Terese Hylander, Lars Ohlsson, Daniel Appelgren, Anette Sundstedt, Kristina Tillerkvist, Hanne R Romedahl, Maria Wigren

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Gillian Dao NyesigaIdogen AB, Lund, Sweden.
Lieneke PoolIdogen AB, Lund, Sweden.
Pavlos C EnglezouIdogen AB, Lund, Sweden.
Terese HylanderIdogen AB, Lund, Sweden.
Lars OhlssonDepartment of Biomedical Sciences, Faculty of Health and Society, Malmö University, Malmö, Sweden.
Daniel AppelgrenDepartment of Health, Medicine and Caring Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Anette SundstedtIdogen AB, Lund, Sweden.
Kristina TillerkvistIdogen AB, Lund, Sweden.
Hanne R RomedahlIdogen AB, Lund, Sweden.
Maria WigrenIdogen AB, Lund, Sweden.
Malmö University · SELinköping University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dendritic cells (DCs) are mediators between innate and adaptive immunity and vital in initiating and modulating antigen-specific immune responses. The most important site for induction of tolerance is the gut mucosa, where TGF-β, retinoic acid, and aryl hydrocarbon receptors collaborate in DCs to induce a tolerogenic phenotype. To mimic this, a novel combination of compounds - the synthetic aryl hydrocarbon receptor (AhR) agonist IGN-512 together with TGF-β and retinoic acid - was developed to create a platform technology for induction of tolerogenic DCs intended for treatment of several conditions caused by unwanted immune activation. These

Indexed as

Immune ToleranceTransforming Growth Factor betaDendritic CellsHumansMucous MembraneTretinoinTransforming Growth Factor betaTretinoinantigen loadingantigen-specific responsecell therapyimmune toleranceregulatory B cells (Bregs)regulatory T cells (Tregs)tolerogenic dendritic cells (tolDCs)

Identifiers

PMID37901231
PMCPMC10613069
OpenAlexW4387601206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.